| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
GMAB
Genmab
|
Jun 14, 2026 | BUY |
Buy
+38.2% avg upside
26 analysts
|
$32.00
26.62% Upside
|
· |
|
TNGX
Tango Therapeutics
|
Jun 08, 2026 | BUY |
Strong Buy
+24.2% avg upside
14 analysts
|
$35.00
25.21% Upside
|
+4.4% |
|
ONC
BeOne Medicines
|
Jun 03, 2026 | BUY |
Strong Buy
+28.6% avg upside
28 analysts
|
$340.00
25.87% Upside
|
-5.9% |
|
CGON
CG Oncology, Inc.
|
May 26, 2026 | HOLD |
Strong Buy
+41.1% avg upside
17 analysts
|
— | -4.0% |
|
CTMX
CytomX Therapeutics
|
May 19, 2026 | BUY |
Strong Buy
+269.4% avg upside
21 analysts
|
$6.00
103.35% Upside
|
-17.3% |
|
TYRA
Tyra Bioscience
|
May 19, 2026 | HOLD |
Strong Buy
+57.9% avg upside
17 analysts
|
— | -3.8% |
|
MIRM
Mirum Pharmaceuticals
|
May 19, 2026 | BUY |
Strong Buy
+7.5% avg upside
21 analysts
|
$145.00
35.30% Upside
|
+12.0% |
|
RVMD
Revolution Medicines
|
May 06, 2026 | BUY |
Strong Buy
-12.2% avg upside
32 analysts
|
$165.00
1.15% Upside
|
+4.4% |
|
CORT
Corcept Therapeutics
|
Mar 26, 2026 | HOLD |
Buy
-45.6% avg upside
15 analysts
|
— | +112.2% |
|
OLMA
Olema Pharmaceuticals
|
Mar 26, 2026 | HOLD |
Strong Buy
+303.7% avg upside
16 analysts
|
— | -34.9% |
|
KRYS
Krystal Biotech
|
Mar 26, 2026 | HOLD |
Strong Buy
-28.3% avg upside
19 analysts
|
— | +35.9% |
|
VSTM
Verastem
|
Oct 10, 2025 | BUY |
Strong Buy
+259.4% avg upside
23 analysts
|
$16.00
288.40% Upside
|
-53.3% |
|
AVBP
ArriVent BioPharma, Inc.
|
Jul 21, 2025 | BUY |
Strong Buy
+37.1% avg upside
15 analysts
|
$37.00
16.54% Upside
|
+45.5% |
|
MNOV
Medicinova
|
Jun 16, 2025 | BUY |
Strong Buy
+460.6% avg upside
5 analysts
|
$5.00
278.72% Upside
|
+3.0% |
|
KYMR
Kymera Therapeutics
|
Jun 03, 2025 | BUY |
Strong Buy
+9.0% avg upside
36 analysts
|
$60.00
33.70% Downside
|
+68.0% |
|
VRDN
Viridian Therapeutics
|
May 21, 2025 | HOLD |
Strong Buy
+103.6% avg upside
32 analysts
|
$19.00
14.23% Upside
|
+17.9% |
|
CRBP
Corbus Pharmaceuticals
|
May 07, 2025 | BUY |
Strong Buy
+338.6% avg upside
20 analysts
|
$28.00
239.02% Upside
|
+77.3% |
|
BCYC
Bicycle Therapeutics
|
May 02, 2025 | HOLD |
Strong Buy
+504.5% avg upside
20 analysts
|
$14.00
250.10% Upside
|
-48.4% |
|
DERM
Journey Medical Corp
|
Mar 27, 2025 | BUY |
Strong Buy
+98.3% avg upside
11 analysts
|
$9.00
44.62% Upside
|
-22.8% |
|
RIGL
Rigel
|
Mar 05, 2025 | HOLD |
Strong Buy
-27.5% avg upside
17 analysts
|
$24.00
27.17% Downside
|
+45.5% |
|
SNDX
Syndax Pharmaceuticals
|
Mar 03, 2025 | BUY |
Strong Buy
+88.7% avg upside
27 analysts
|
$29.00
52.69% Upside
|
+38.2% |
|
GERN
Geron
|
Feb 26, 2025 | HOLD |
Strong Buy
+240.0% avg upside
19 analysts
|
$2.00
58.75% Upside
|
+2.5% |
|
FHTX
Foghorn Therapeutics
|
Jan 29, 2025 | BUY |
Strong Buy
+187.5% avg upside
17 analysts
|
$10.00
140.93% Upside
|
+45.0% |
|
XFOR
X4 Pharmaceuticals
|
Nov 18, 2024 | HOLD |
Strong Buy
+496.4% avg upside
15 analysts
|
$15.00
255.45% Upside
|
-67.6% |
|
OVID
Ovid Therapeutics
|
Sep 27, 2024 | BUY |
Strong Buy
+108.4% avg upside
17 analysts
|
$3.00
32.09% Upside
|
+46.6% |
|
ALLO
Allogene Therapeutics
|
May 14, 2024 | BUY |
Strong Buy
+662.8% avg upside
28 analysts
|
$7.00
250.06% Upside
|
-67.9% |
|
PDSB
PDS Biotechnology
|
Aug 14, 2023 | BUY |
Strong Buy
+1493.1% avg upside
11 analysts
|
$14.00
1366.04% Upside
|
-43.3% |
|
INKT
MiNK Therapeutics
|
Mar 21, 2023 | BUY |
Strong Buy
+81.2% avg upside
6 analysts
|
$7.00
42.39% Downside
|
-56.4% |
|
DNTH
Dianthus Therapeutics
|
Dec 30, 2022 | HOLD |
Strong Buy
+8.9% avg upside
29 analysts
|
— | +62.5% |
|
INAB
IN8bio
|
Dec 30, 2022 | HOLD |
Strong Buy
+4095.8% avg upside
5 analysts
|
— | -40.3% |
|
INFIQ
Infinity Pharmaceuticals
|
Dec 30, 2022 | HOLD |
Buy
+647142757.1% avg upside
8 analysts
|
— | -99.6% |
|
ENTX
Entera Bio
|
Aug 19, 2022 | HOLD |
Strong Buy
+354.6% avg upside
3 analysts
|
— | -62.3% |
|
FBRX
Forte Biosciences
|
Nov 26, 2021 | HOLD |
Strong Buy
+128.0% avg upside
14 analysts
|
— | -63.1% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.